389 related articles for article (PubMed ID: 28415646)
1. Combination of immunohistochemistry, FISH and RT-PCR shows high incidence of Xp11 translocation RCC: comparison of three different diagnostic methods.
Lee HJ; Shin DH; Noh GY; Kim YK; Kim A; Shin N; Lee JH; Choi KU; Kim JY; Lee CH; Sol MY; Rha SH; Park SW
Oncotarget; 2017 May; 8(19):30756-30765. PubMed ID: 28415646
[TBL] [Abstract][Full Text] [Related]
2. TFE3 break-apart FISH has a higher sensitivity for Xp11.2 translocation-associated renal cell carcinoma compared with TFE3 or cathepsin K immunohistochemical staining alone: expanding the morphologic spectrum.
Rao Q; Williamson SR; Zhang S; Eble JN; Grignon DJ; Wang M; Zhou XJ; Huang W; Tan PH; Maclennan GT; Cheng L
Am J Surg Pathol; 2013 Jun; 37(6):804-15. PubMed ID: 23598965
[TBL] [Abstract][Full Text] [Related]
3. Newly designed break-apart and ASPL-TFE3 dual-fusion FISH assay are useful in diagnosing Xp11.2 translocation renal cell carcinoma and ASPL-TFE3 renal cell carcinoma: a STARD-compliant article.
Chen X; Yang Y; Gan W; Xu L; Ye Q; Guo H
Medicine (Baltimore); 2015 May; 94(19):e873. PubMed ID: 25984679
[TBL] [Abstract][Full Text] [Related]
4. Validation and utilization of a TFE3 break-apart FISH assay for Xp11.2 translocation renal cell carcinoma and alveolar soft part sarcoma.
Pradhan D; Roy S; Quiroga-Garza G; Cieply K; Mahaffey AL; Bastacky S; Dhir R; Parwani AV
Diagn Pathol; 2015 Sep; 10():179. PubMed ID: 26415891
[TBL] [Abstract][Full Text] [Related]
5. Utilization of a TFE3 break-apart FISH assay in a renal tumor consultation service.
Green WM; Yonescu R; Morsberger L; Morris K; Netto GJ; Epstein JI; Illei PB; Allaf M; Ladanyi M; Griffin CA; Argani P
Am J Surg Pathol; 2013 Aug; 37(8):1150-63. PubMed ID: 23715164
[TBL] [Abstract][Full Text] [Related]
6. Usefulness of a break-apart FISH assay in the diagnosis of Xp11.2 translocation renal cell carcinoma.
Kim SH; Choi Y; Jeong HY; Lee K; Chae JY; Moon KC
Virchows Arch; 2011 Sep; 459(3):299-306. PubMed ID: 21773754
[TBL] [Abstract][Full Text] [Related]
7. PRCC-TFE3 dual-fusion FISH assay: A new method for identifying PRCC-TFE3 renal cell carcinoma in paraffin-embedded tissue.
Xiong L; Chen X; Liu N; Wang Z; Miao B; Gan W; Li D; Guo H
PLoS One; 2017; 12(9):e0185337. PubMed ID: 28949976
[TBL] [Abstract][Full Text] [Related]
8. TFE3-Fusion Variant Analysis Defines Specific Clinicopathologic Associations Among Xp11 Translocation Cancers.
Argani P; Zhong M; Reuter VE; Fallon JT; Epstein JI; Netto GJ; Antonescu CR
Am J Surg Pathol; 2016 Jun; 40(6):723-37. PubMed ID: 26975036
[TBL] [Abstract][Full Text] [Related]
9. Xp11 Translocation Renal Cell Carcinomas (RCCs) With RBM10-TFE3 Gene Fusion Demonstrating Melanotic Features and Overlapping Morphology With t(6;11) RCC: Interest and Diagnostic Pitfall in Detecting a Paracentric Inversion of TFE3.
Xia QY; Wang XT; Zhan XM; Tan X; Chen H; Liu Y; Shi SS; Wang X; Wei X; Ye SB; Li R; Ma HH; Lu ZF; Zhou XJ; Rao Q
Am J Surg Pathol; 2017 May; 41(5):663-676. PubMed ID: 28288037
[TBL] [Abstract][Full Text] [Related]
10. A case of bilateral renal cell carcinoma associated with long-term dialysis showing false-positive immunoreactivity for TFE3 as Xp11 translocation renal cell carcinoma.
Kurisaki-Arakawa A; Saito T; Takahashi M; Mitani K; Fukumura Y; Nagashima Y; Argani P; Yao T
Int J Clin Exp Pathol; 2013; 6(11):2585-90. PubMed ID: 24228124
[TBL] [Abstract][Full Text] [Related]
11. RBM10-TFE3 Renal Cell Carcinoma: A Potential Diagnostic Pitfall Due to Cryptic Intrachromosomal Xp11.2 Inversion Resulting in False-negative TFE3 FISH.
Argani P; Zhang L; Reuter VE; Tickoo SK; Antonescu CR
Am J Surg Pathol; 2017 May; 41(5):655-662. PubMed ID: 28296677
[TBL] [Abstract][Full Text] [Related]
12. SFPQ/PSF-TFE3 renal cell carcinoma: a clinicopathologic study emphasizing extended morphology and reviewing the differences between SFPQ-TFE3 RCC and the corresponding mesenchymal neoplasm despite an identical gene fusion.
Wang XT; Xia QY; Ni H; Ye SB; Li R; Wang X; Shi SS; Zhou XJ; Rao Q
Hum Pathol; 2017 May; 63():190-200. PubMed ID: 28315422
[TBL] [Abstract][Full Text] [Related]
13. Xp11 translocation renal cell carcinoma and clear cell renal cell carcinoma with TFE3 strong positive immunostaining: morphology, immunohistochemistry, and FISH analysis.
Yang B; Duan H; Cao W; Guo Y; Liu Y; Sun L; Zhang J; Sun Y; Ma Y
Mod Pathol; 2019 Oct; 32(10):1521-1535. PubMed ID: 31175325
[TBL] [Abstract][Full Text] [Related]
14. [Clinicopatholigic features of renal cell carcinoma associated with chromosome X inversion harboring gene fusions involving TFE3].
Zhao YN; Wang XT; Xia QY; Wang GP; Sun SY; Zhao LF; Zhou XJ; Rao Q
Zhonghua Bing Li Xue Za Zhi; 2018 Aug; 47(8):574-579. PubMed ID: 30107660
[No Abstract] [Full Text] [Related]
15. Cathepsin-K immunoreactivity distinguishes MiTF/TFE family renal translocation carcinomas from other renal carcinomas.
Martignoni G; Pea M; Gobbo S; Brunelli M; Bonetti F; Segala D; Pan CC; Netto G; Doglioni C; Hes O; Argani P; Chilosi M
Mod Pathol; 2009 Aug; 22(8):1016-22. PubMed ID: 19396149
[TBL] [Abstract][Full Text] [Related]
16. A novel partner of TFE3 in the Xp11 translocation renal cell carcinoma: clinicopathological analyses and detection of EWSR1-TFE3 fusion.
Fukuda H; Kato I; Furuya M; Tanaka R; Takagi T; Kondo T; Nagashima Y
Virchows Arch; 2019 Mar; 474(3):389-393. PubMed ID: 30552521
[TBL] [Abstract][Full Text] [Related]
17. Renal cell carcinoma associated with transcription factor E3 expression and Xp11.2 translocation: incidence, characteristics, and prognosis.
Klatte T; Streubel B; Wrba F; Remzi M; Krammer B; de Martino M; Waldert M; Marberger M; Susani M; Haitel A
Am J Clin Pathol; 2012 May; 137(5):761-8. PubMed ID: 22523215
[TBL] [Abstract][Full Text] [Related]
18. PSF/SFPQ is a very common gene fusion partner in TFE3 rearrangement-associated perivascular epithelioid cell tumors (PEComas) and melanotic Xp11 translocation renal cancers: clinicopathologic, immunohistochemical, and molecular characteristics suggesting classification as a distinct entity.
Rao Q; Shen Q; Xia QY; Wang ZY; Liu B; Shi SS; Shi QL; Yin HL; Wu B; Ye SB; Li L; Chen JY; Pan MH; Li Q; Li R; Wang X; Zhang RS; Yu B; Ma HH; Lu ZF; Zhou XJ
Am J Surg Pathol; 2015 Sep; 39(9):1181-96. PubMed ID: 26274027
[TBL] [Abstract][Full Text] [Related]
19. TMED6-COG8 is a novel molecular marker of TFE3 translocation renal cell carcinoma.
Xu Y; Rao Q; Xia Q; Shi S; Shi Q; Ma H; Lu Z; Chen H; Zhou X
Int J Clin Exp Pathol; 2015; 8(3):2690-9. PubMed ID: 26045774
[TBL] [Abstract][Full Text] [Related]
20. TFE3 translocation and protein expression in renal cell carcinoma are correlated with poor prognosis.
Lee HJ; Shin DH; Kim SY; Hwang CS; Lee JH; Park WY; Choi KU; Kim JY; Lee CH; Sol MY; Rha SH; Park SW
Histopathology; 2018 Nov; 73(5):758-766. PubMed ID: 29968390
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]